A.S. Coates,E.P. Winer,A. Goldhirsch,R.D. Gelber,M. Gnant,M. Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Panel Members,Fabrice André,José Baselga,Jonas Bergh,Hervé Bonnefoi,Harold Burstein,Fatima Cardoso,Monica Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Viviana Galimberti,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela Goodwin,Nadia Harbeck,Daniel F. Hayes,Jens Huober,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Monica Morrow,Roberto Orecchia,C. Kent Osborne,Ann H. Partridge,Lorena de la Peña,Martine J. Piccart-Gebhart,Kathleen I. Pritchard,Emiel J.T. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Zhi-Ming Shao,Ian Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Gunter von Minckwitz,Toru Watanabe,Timothy Whelan,Eric P. Winer,Binghe Xu

Abstract:The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation of regional nodes in node-positive disease. Considering subdivisions within luminal disease, the Panel was more concerned with indications for the use of specific therapies, rather than surrogate identification of intrinsic subtypes as measured by multiparameter molecular tests. For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy. For premenopausal patients with endocrine responsive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk. The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility. The Panel noted increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also carried prognostic information for late relapse. The Panel noted that the results of such tests, where available, were frequently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal disease, but noted that threshold values had not been established for this purpose for any of these tests. Multiparameter molecular assays are expensive and therefore unavailable in much of the world. The majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world. In these areas, less expensive pathology tests may provide valuable information. The Panel recommendations on treatment are not intended to apply to all patients, but rather to establish norms appropriate for the majority. Again, economic considerations may require that less expensive and only marginally less effective therapies may be necessary in less resourced areas. Panel recommendations do not imply unanimous agreement among Panel members. Indeed, very few of the 200 questions received 100% agreement from the Panel. In the text below, wording is intended to convey the strength of Panel support for each recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available at Annals of Oncology online.

[Effect of supplementary vitamin administration on free amino acids in the liver and brain of rats with alcoholic intoxication].

Heterogeneity of Clones of Saccharomyces Derived from Haploid Ascospores.

[The laryngeal tube].

Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative

Barriers to making recommendations about medical tests: a qualitative study of European guideline developers

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Epitope mapping of homologous and cross-reactive antigens by monoclonal antibodies to streptococcal cell membrane (mAb to SCM).

Calcium Signalling in Secretory Cells

Characterization of the pituitary response in the TRH test by kinetic modeling.

Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis

Hookah smoking seduces US young adults.

CoCanCPG. Coordination of cancer clinical practice in Europe

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Cryptographic architecture for co-process on consumer electronics devices

Enduring Consensus Guidelines for Cervical Cancer Screening and Management: Introduction to the Scope and Process

Dissemination and implementation science frameworks and strategies to increase breast cancer screening for at-risk women in the United States: A scoping review

Engaging Multidisciplinary Teams to Develop Pragmatic Clinical Practice Guidelines to Support Management of Patients With High-Risk Breast Lesions

Organizational impact of systemic implementation of digital breast tomosynthesis as a primary test for breast cancer screening in Italy

Development and pilot implementation of a novel protocol to assess capacity and readiness of health systems to adopt HPV detection-based cervical cancer screening in Europe

Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation